# City Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/city-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.citytx.com
- Total disclosed funding: $235M
- Latest round: Series B (Jun 8, 2026)
- Investors on record: 12

## About

Based in Massachusetts, US, and founded by co-founders Sebastian Trousil Ph.D. and John Maraganore Ph.D., City Therapeutics Inc. operates as a provider of engineered small interfering RNAs (siRNAs) to biotechnology firms and healthcare organizations for developing innovative RNAi therapies. In June 2026, City Therapeutics Inc. raised USD 99.5 million in series B funding from Sofinnova Investments, Viking Global Investors, Casdin Capital, NYBC Ventures, AN Ventures, ARCH Venture Partners, Fidelity Investments, Invus Financial Advisors, Regeneron Ventures, Rock Springs Capital, and Slate Path Capital Lp.

The company provides a wide range of biotechnology solutions, such as small interfering RNAs (siRNAs), engineered RNAi trigger molecules, targeting ligands for enhanced cellular uptake, and advanced therapeutic targets. Additionally, the firm also provides services such as clinical development optimization for RNAi-based medicines and support for therapeutic target identification.

The company plans to use its proceeds from June 2026 funding to advance its ribonucleic acid interference platform, develop its drug pipeline including clinical trials, and support business development activities.

## Funding rounds

- Series B, Jun 8, 2026, $100M — ARCH Venture Partners, Sofinnova Investments, Viking Global Investors, Fidelity Investments, Casdin Capital, Invus Financial Advisors, Slate Path Capital Lp, NYBC Ventures, AN Ventures, Regeneron Ventures, Rock Springs Capital
- Series A, Oct 8, 2024, $135M — ARCH Venture Partners, Invus [DUP], Fidelity Investments, Rock Springs Capital, Slate Path Capital Lp, AN Ventures, Regeneron Ventures

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Invus [DUP] — Series A
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series A, Series B
- Rock Springs Capital — Series A, Series B
- Slate Path Capital Lp — Series A, Series B
- AN Ventures (https://capitalatlas.ai/funds/an-ventures) — Series A, Series B
- Regeneron Ventures (https://capitalatlas.ai/funds/regeneron-ventures) — Series A, Series B
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series B
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- Invus Financial Advisors (https://capitalatlas.ai/funds/invus-financial-advisors) — Series B
- NYBC Ventures (https://capitalatlas.ai/funds/nybc-ventures) — Series B